Skymount Medical, using research developed at Louisiana State University (LSU), launched Inhibinol â¢, a dietary supplement formulated using artificial intelligence (AI) to support the immune system, essential antioxidant functions and overall cardiovascular health. The launch comes as interest in dietary supplements for better health grows exponentially, with a global market for these products is expected to reach a record value of 306.8 billion by 2026.
âThe pandemic has created a lot of uncertainty regarding the health of the immune system,â said Chris Galliano, CTO of Skymount Medical. âAI-derived Inhibinol â¢ is the first product of its kind and a prime example of a smarter generation of dietary supplements. We hope that the product will allow people to take charge and have more confidence in their own health and well-being. Basically, you can think of Inhibinol â¢ as a personal health shield.
Designed to be a highly effective blend of natural extracts, essential vitamins and minerals, Inhibinol â¢ was discovered and developed by the platform called DeepDrug â¢. By leveraging AI, DeepDrug â¢ can evaluate and correlate millions of molecular combinations at a rate unattainable by traditional research methods.
DeepDrug â¢ formulations give rise to new products, such as Inhibinol â¢, intended to help correct vitamin / mineral imbalance in the body. Inhibinol â¢ also relies on familiar ingredients, such as ginseng and chamomile, to fight free radicals, which can negatively impact cell function and overall immune health.
DeepDrug â¢ was created in 2012 by the LSU research team and is led by Supratik Mukhopadhyay, Associate Professor in the Department of Computer Science at LSU and expert in AI applications in health. To date, his findings have obtained three US patents, and at least four more are currently pending.
Learn more about Skymount Medical here.
Click on here to learn more about Inhibinol â¢.